Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?

Simply Wall St.07-19

Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652255494?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-19 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652255494","market":"sg","top_or_hot":-1,"title":"Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?","media":"Simply Wall St.","content":"<div>\n<p>Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/has-sarepta-therapeutics-srpt-fallen-below-fair-value-after\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-19 10:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/has-sarepta-therapeutics-srpt-fallen-below-fair-value-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/has-sarepta-therapeutics-srpt-fallen-below-fair-value-after\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/has-sarepta-therapeutics-srpt-fallen-below-fair-value-after","article_id":"2652255494","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/has-sarepta-therapeutics-srpt-fallen-below-fair-value-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652255494","pubTimestamp":1784427558,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory progress that could influence how investors think about what the shares are worth today.\n\nOver the past three years, Sarepta Therapeutics has fallen 83.7%, which places the current valuation in the context of a prolonged drawdown rather than a recent rally.\nThe FDA’s acceptance of supplemental...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","SRPU":"2倍做多SRPT ETF-Tradr","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4097":"系统软件","GXDW":"Global X Dorsey Wright Thematic ETF","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","VGFPF":"Vanguard Funds PLC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SRPT":"Sarepta Therapeutics","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PRGS":"Progress Software Corporation","TSPA":"T. Rowe Price U.S. Equity Research ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","BK4588":"碎股","VOTE":"TCW Transform 500 ETF"},"translate_title":"在 FDA 取得进展后，Sarepta Therapeutics (SRPT) 是否已跌破公允价值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":0.89,"GXDW":0.89,"SRPU":0.6,"VGFPF":0.89,"FEBU":0.89,"VOTE":0.89,"PRGS":1.5,"LABU":1.5,"TSPA":0.69,"SRPT":1.5},"content_text":"Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory progress that could influence how investors think about what the shares are worth today.  Over the past three years, Sarepta Therapeutics has fallen 83.7%, which places the current valuation in the context of a prolonged drawdown rather than a recent rally. The FDA’s acceptance of supplemental applications to convert key Duchenne muscular dystrophy therapies to traditional approval may support confidence in Sarepta Therapeutics’ revenue durability, while any future regulatory or clinical setbacks remain a central risk to the stock’s valuation. On Simply Wall St’s broader checks, Sarepta Therapeutics scores 3 out of 6 on valuation, which points to a mixed picture rather than a clear bargain or clear overvaluation.  The issue now is whether Sarepta Therapeutics’ current share price already reflects the regulatory progress and recovery in shorter term returns, or if the long three year decline still leaves room for a more constructive valuation case. Find out why Sarepta Therapeutics' 22.3% return over the last year is lagging behind its peers. AdvertisementIs Sarepta Therapeutics Getting Expensive on Earnings? The P/E ratio is a useful cross check for Sarepta Therapeutics because it anchors the stock to the earnings it is already producing. Sarepta trades at about 27.9x earnings, which sits above the Biotechs industry average of roughly 17.3x but below the peer group average of about 36.9x. That mix suggests investors are paying more than the typical biotech stock per dollar of earnings, while not assigning the same multiple as some closer peers. The Fair Ratio model points to a P/E of around 5.2x for Sarepta, and the large gap to the current 27.9x indicates the framework is heavily discounting the company for its risk profile and earnings quality rather than offering a precise target. Despite the recent lift in Sarepta Therapeutics shares after the FDA accepted supplemental applications for its Duchenne therapies, the stock still screens as expensive on this earnings based lens. On this P/E measure, Sarepta Therapeutics stock screens as expensive relative to this framework. NasdaqGS:SRPT P/E Ratio as at Jul 2026 See what the numbers say about this price — find out in our valuation breakdown. The Sarepta Therapeutics Narrative: What Would Justify Today's Price? Simply Wall St Narratives take Sarepta Therapeutics' valuation puzzle a step further by spelling out what kind of future growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than it trades for today, and they sit on the company’s Community page. Rather than relying on a single multiple or model, each narrative sets out its own fair value assumptions so you can compare them with actual results over time. Community views on Sarepta Therapeutics sit at opposite ends of the spectrum, with one camp seeing reset upside and the other focused on execution and regulatory risk. Bull case: 20% undervalued \"Development and commercialization of other programs like the LGMD and siRNA platforms represent additional revenue streams, positively impacting overall financial health...\" Read the full Bull Case to see why Sarepta Therapeutics could be undervalued Bear case: 145% overvalued \"Overreliance on key products, delayed capacity expansion, and high upfront investments heighten risks of market saturation, revenue concentration, and sustained operating losses...\" Read the full Bear Case to see why Sarepta Therapeutics could be overvalued Do you think there's more to the story for Sarepta Therapeutics? Head over to our Community to see what others are saying! The Bottom Line For Sarepta Therapeutics, the current setup leans toward overvalued on earnings, with a clear gap between the Fair Ratio model and where the stock trades today. That reflects a market willing to pay up for its Duchenne muscular dystrophy portfolio, while the framework heavily penalises execution, regulatory and earnings quality risk. The crux for investors is whether Sarepta can translate its regulatory progress into durable, higher quality earnings that make today’s richer multiple feel justified rather than stretched.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652255494","isCrawlerRequest":true}